Brief Overview of Therapeutic Landscape for R/R MM
Panelists discuss how emerging therapies like bispecific antibodies, chimeric antigen receptor (CAR) T cells, and novel drug combinations are reshaping treatment options for patients with relapsed/refractory multiple myeloma (R/R MM) who have exhausted standard approaches.
Video content above is prompted by the following:
- Provide a brief historical overview of the therapeutic landscape for R/R MM.
- How has the landscape evolved since, and what challenges/unmet needs remain?
- Comment on the recent updates surrounding the management of R/R MM with bispecifics:
- MonumenTAL-1: Long-Term Efficacy and Safety Results
- What does the long-term efficacy data from MonumenTAL-1 tell us about the durability of responses with talquetamab in heavily pretreated patients?
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
